Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Psoriasis entities : Bristol-myers squibb company save search
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.36%
H: 0.21%
C: -0.87%
reveal psoriasis living
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.01%
H: 0.75%
C: 0.18%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.1%
H: 0.71%
C: 0.62%
approval psoriasis treatment
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.0%
H: 0.25%
C: -0.48%
treatment chmp psoriasis positive
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published: 2022-09-10 (Crawled : 08:20) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment drug psoriasis food plague
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
Global $53 Bn Psoriasis Drugs Markets 2021-2030: Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies, TNF-Alpha, PDE4, & Interleukin Inhibitors, Oral, Parenteral, Topical
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.6 -0.69% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
| Email alert
Add to watchlist
drug psoriasis therapy
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
Global Psoriasis Drugs Market to Reach $53,210.6 Million by 2030, says P&S Intelligence
Published: 2021-04-07 (Crawled : 08:00) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.09%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.1%
H: 0.45%
C: 0.04%
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
|
| O: 0.58%
H: 0.28%
C: -0.47%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.05%
H: 0.15%
C: -0.32%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.05%
H: 0.85%
C: 0.08%
BHC | $8.6 -0.69% 0.0% 2.2M
|
Health Technology
|
| O: -0.1%
H: 1.33%
C: 1.09%
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.37%
H: 0.83%
C: -0.02%
drug psoriasis
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.